News|Articles|February 2, 2026

5 Cardiology Headlines You Missed in January 2026

Catch up with major FDA decisions, key guidelines updates, and more.

Although the US Food and Drug Administration (FDA) had a relatively quiet January, the American Heart Association (AHA) and American Diabetes Association (ADA) made up for it with several significant guideline updates and statistics releases. Additionally, the Dietary Guidelines for Americans 2025-2030 provided a plethora of new government-backed suggestions, both supported and questioned by cardiologists and endocrinologists across the country.

Related to this article

October 30th, 2026

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

The plasmid DNA immunotherapy Voceryq gained FDA accelerated approval after 27% of RRP-001 patients needed no surgery for 12 months.

October 30th, 2026

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism: RemIND data, bleeding counseling, and where it fits in practice

October 30th, 2026

Mitapivat PDUFA Date for Sickle Cell Disease Extended to February 2027

The FDA has pushed its decision on mitapivat for sickle cell disease to February 1, 2027, while it reviews updated safety data to decide whether a REMS is needed.

October 28th, 2026

Weight-Loss Program Cuts Vascular Events by 67% After Minor Stroke, TIA

In the SCENARIO trial, a 15-week weight-loss program cut recurrent vascular events by 67% in patients with obesity after minor ischemic stroke or TIA.

October 26th, 2026

Which LVO Stroke Patients Benefit from Edaravone Dexborneol Before EVT?

Edaravone dexborneol before thrombectomy improved 90-day independence only in LVO stroke patients with clinical-radiological mismatch in TASTE-2.

October 23rd, 2026

FDA Approves Subcutaneous Risankizumab Induction for Crohn’s Disease

Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.

November 2nd, 2026

FDA Label Change Drops Mandatory TB Screening for Risankizumab

The FDA updated the risankizumab label to make pretreatment TB evaluation a matter of clinical judgment across all indications, including psoriasis.

November 2nd, 2026

What Phase 2 and 3 Data Show for Topical Difamilast in Atopic Dermatitis

Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.